Diffrence between Sodium nitroprusside and NTG
Both are vasodilators used in hypertensive emergencies, but they differ significantly in mechanism, selectivity, and toxicity. SNP dilates arteries and veins equally (balanced), while NTG (nitroglycerin) predominantly dilates veins at low doses with some arterial effect at higher doses. SNP is more potent and faster-acting, but carries a risk of cyanide toxicity with prolonged use.
Searching sources...
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Here is the complete comparison:
Sodium Nitroprusside (SNP) vs. Nitroglycerin (NTG)
Mechanism of Action
Both are nitrovasodilators that ultimately work through the same final pathway: they release nitric oxide (NO) → activate guanylyl cyclase → increase cGMP → decrease intracellular calcium → relax vascular smooth muscle. However, their routes to NO differ:
- SNP: Non-enzymatic reaction; in red blood cells, Fe²⁺ of oxyhemoglobin donates an electron to nitroprusside, releasing the active nitroso (NO) group along with 5 cyanide ions and methemoglobin.
- NTG: Undergoes rapid reductive hydrolysis in the liver and blood by glutathione-organic nitrate reductase, producing nitric oxide. One metabolic product is nitrite, which can convert Hb to methemoglobin.
(Morgan & Mikhail's Clinical Anesthesiology, 7e)
Vascular Selectivity - The Core Difference
| Property | SNP | NTG |
|---|---|---|
| Venous dilation | Yes (balanced) | Yes (predominant at low doses) |
| Arterial dilation | Yes (balanced) | Minimal at low doses; increases at higher doses |
| Net effect | Balanced arterial + venous dilator | Predominantly venodilator |
| Effect on preload | Reduces preload + afterload | Primarily reduces preload |
| Effect on afterload | Primarily reduces afterload | Minimal at low doses |
Hemodynamic Effects
| Parameter | SNP | NTG |
|---|---|---|
| Cardiac output | No change (or slight decrease) in normal heart; increases in heart failure via afterload reduction | Similar, but mainly via preload reduction |
| Heart rate | Reflex tachycardia (via renin + catecholamines) | Unchanged or minimally increased |
| BP reduction | Rapid, potent, precise titration | Effective but milder |
| Rebound hypertension | More likely on discontinuation | Less likely |
Clinical Uses
| Indication | SNP | NTG |
|---|---|---|
| Hypertensive emergency | First-line; gold standard | Yes, especially with ACS or pulmonary edema |
| Heart failure / cardiogenic shock | Useful - reduces both preload + afterload; improves forward flow | Useful - preferred in pulmonary edema (preload reduction) |
| Coronary artery disease / ACS | Contraindicated - causes coronary steal phenomenon | Preferred - redistributes flow to ischemic subendocardium; relieves coronary spasm |
| Myocardial ischemia relief | No (worsens it via steal) | Yes |
| Aortic dissection | Yes (combined with beta-blocker) | Alternative |
| Controlled hypotension in surgery | Yes | Less commonly used |
| Obstetrics (uterine relaxation) | No | Yes - 50-100 mcg IV bolus works as uterine relaxant |
| Acute MI | Relatively contraindicated | Preferred |
(Barash 9e, Fuster and Hurst's The Heart 15e, Comprehensive Clinical Nephrology 7e)
Coronary Steal - Key Exam Point
- SNP causes coronary steal: dilates non-stenotic vessels but cannot dilate already maximally dilated vessels beyond a stenosis → diverts flow away from ischemic areas → worsens ischemia.
- NTG does the opposite - it redistributes coronary blood flow to ischemic subendocardial areas and relieves coronary artery spasm. This is why NTG is favored in ACS while SNP is relatively contraindicated.
Dosing & Administration
| Parameter | SNP | NTG |
|---|---|---|
| Route | IV infusion only | IV infusion, sublingual, transdermal |
| Concentration | 100 mcg/mL | 100 mcg/mL |
| Infusion rate | 0.25-5 mcg/kg/min (up to 10 mcg/kg/min short-term) | 0.5-5 mcg/kg/min |
| Onset | 1-2 minutes | ~4 min sublingual; rapid IV |
| Offset | 1-10 minutes after stopping | Similar rapid offset IV |
| Light sensitivity | Yes - must be covered with opaque foil | Yes |
| Monitoring | Intra-arterial BP monitoring recommended | Standard |
Toxicity
SNP - Cyanide & Thiocyanate Toxicity
- SNP releases 5 cyanide ions per molecule on metabolism.
- Cyanide can: (1) bind methemoglobin (safe) → cyanmethemoglobin; (2) be converted by rhodanese (liver/kidney) with thiosulfate → thiocyanate (less toxic); (3) bind cytochrome oxidase → impairs O₂ utilization → cyanide toxicity.
- Signs of cyanide toxicity: metabolic acidosis, arrhythmias, elevated venous O₂ content (cells can't use O₂), tachyphylaxis (first sign - resistance to hypotensive effect).
- Risk factors: doses >500 mcg/kg/day, infusion >2 mcg/kg/min for hours, renal failure.
- Treatment: sodium thiosulfate (sulfur donor), hydroxocobalamin (forms cyanocobalamin).
- Thiocyanate toxicity (with prolonged use or renal failure): weakness, disorientation, psychosis, muscle spasms, convulsions; serum levels >10 mg/dL confirm it.
- Rarely: methemoglobinemia, delayed hypothyroidism (thiocyanate inhibits iodide uptake).
NTG - Comparatively Safer
- Main toxicities: headache (cerebral vessel dilation), hypotension.
- Low-level methemoglobinemia possible (from nitrite metabolite) - treat with methylene blue 1-2 mg/kg IV.
- No cyanide toxicity.
- Inhibits platelet aggregation (rarely causes significant bleeding).
Pulmonary Effects (Both Drugs)
Both dilate pulmonary vasculature and can:
- Inhibit hypoxic pulmonary vasoconstriction (HPV)
- Increase V/Q mismatch and venous admixture
- Decrease arterial oxygenation
Additionally, NTG relaxes bronchial smooth muscle.
Summary Table
| Feature | SNP | NTG |
|---|---|---|
| Vasodilation pattern | Balanced A + V | Predominantly venous |
| Dominant effect | Afterload + preload | Preload |
| Coronary effect | Steal - harmful | Redistributes flow - beneficial |
| ACS / Ischemia | Contraindicated | Preferred |
| Pulmonary edema | Useful | Preferred |
| Toxicity | Cyanide, thiocyanate | Headache, methemoglobin (rare) |
| Monitoring required | Intra-arterial BP | Standard |
| Routes | IV only | IV / SL / transdermal |
| Tachyphylaxis | Yes (early cyanide sign) | Less prominent |
| Rebound hypertension | More likely | Less likely |
(Sources: Katzung Basic & Clinical Pharmacology 16e; Morgan & Mikhail's Clinical Anesthesiology 7e; Barash Clinical Anesthesia 9e; Fuster & Hurst's The Heart 15e)
This is a shared conversation. Sign in to Orris to start your own chat.